Home › Research › Drug development
Interaction of Glucagon-Like Peptide 1 and Its Analogues with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity
Litus EA, Shevelyova MP, Vologzhannikova AA, Deryusheva EI, Chaplygina AV, Rastrygina VA, Machulin AV, Alikova VD et al.. International journal of molecular sciences, 2025-04-24
Topic: Brain proteins, microglia and lab models
Plain-language summary
Clinical data, animal and cell studies show that some antidiabetic drugs, including glucagon-like peptide 1 receptor agonists (GLP-1RAs), exert therapeutic effects in Alzheimer's disease (AD) via modulation of amyloid-β peptide (Aβ) metabolism. Meanwhile, the direct interactions of GLP-1RAs with Aβ and their functional consequences remain unexplored. The interaction with monomeric Aβ40/Aβ42 of GLP-1(7-37) and its several analogues (semaglutide (Sema), liraglutide (Lira), exenatide (Exen)) was studied by biolayer interferometry and surface plasmon resonance spectroscopy.
What this study adds
Evidence grade: Low
This laboratory study examined the direct interactions of GLP-1(7-37) and its analogues semaglutide, liraglutide and exenatide with monomeric Aβ40/Aβ42 and their effects on Aβ fibrillation and cytotoxicity. It notes that these direct interactions and their functional consequences had remained unexplored.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Litus, E. A., Shevelyova, M. P., Vologzhannikova, A. A., Deryusheva, E. I., Chaplygina, A. V., Rastrygina, V. A., et al. (2025). Interaction of Glucagon-Like Peptide 1 and Its Analogues with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity. International journal of molecular sciences. https://doi.org/10.20944/preprints202504.2038.v1
Vancouver
Litus EA, Shevelyova MP, Vologzhannikova AA, Deryusheva EI, Chaplygina AV, Rastrygina VA, et al. Interaction of Glucagon-Like Peptide 1 and Its Analogues with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity. International journal of molecular sciences. 2025. doi:10.20944/preprints202504.2038.v1.
BibTeX
@article{litus2025-50e87e79,
author = {Litus, E. A. and Shevelyova, M. P. and Vologzhannikova, A. A. and Deryusheva, E. I. and Chaplygina, A. V. and Rastrygina, V. A. and Machulin, A. V. and Alikova, V. D. and others},
title = {{Interaction of Glucagon-Like Peptide 1 and Its Analogues with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity}},
journal = {International journal of molecular sciences},
year = {2025},
doi = {10.20944/preprints202504.2038.v1},
url = {https://doi.org/10.20944/preprints202504.2038.v1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Meanwhile, the direct interactions of GLP-1RAs with Aβ and their functional consequences remain unexplored.
- The interaction with monomeric Aβ40/Aβ42 of GLP-1(7-37) and its several analogues (semaglutide (Sema), liraglutide (Lira), exenatide (Exen)) was studied by biolayer interferometry and surface plasmon resonance spectroscopy.
- Quaternary structure of the GLP-1RAs was investigated by dynamic light scattering.
- The effect of GLP-1RAs on Aβ fibrillation was assessed by Thioflavin T assay and electron microscopy.
Why it matters
This laboratory study examined the direct interactions of GLP-1(7-37) and its analogues semaglutide, liraglutide and exenatide with monomeric Aβ40/Aβ42 and their effects on Aβ fibrillation and cytotoxicity. It notes that these direct interactions and their functional consequences had remained unexplored.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 24 of the 64 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International journal of molecular sciences) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40362335) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 24 of the 64 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.